Allergy, Immunology, and ENT

Latest News

FDA accepts sBLA for dupilumab to treat CRSwNP in patients aged 12 to 17 years | Image Credit: © Araki Illustrations - © Araki Illustrations - stock.adobe.com.
FDA accepts sBLA for dupilumab to treat CRSwNP in patients aged 12 to 17 years

May 13th 2024

The federal agency has accepted the sBLA for Priority Review designation, with a target action date of September 15, 2024.

Higher BMI, obesity probability not associated with early peanut introduction | Image Credit: © Stepan Popov - © Stepan Popov - stock.adobe.com.
Higher BMI, obesity probability not associated with early peanut introduction

May 3rd 2024

FDA approves mavorixafor as first drug for WHIM syndrome | Image Credit: © Calin - © Calin - stock.adobe.com.
FDA approves mavorixafor as first drug for WHIM syndrome

April 29th 2024

Image Credit: © Elena Medoks - © Elena Medoks - stock.adobe.com.
Viaskin milk patch demonstrates mixed results, phase 1/2 data shows

March 1st 2024

Robert Wood, MD | Image Credit: Hopkinsmedicine.org
Experts share their thoughts on the omalizumab OUtMATCH phase 3 data

February 29th 2024

More News


Site Logo

Wheeze in Preschool Children:

April 1st 2007

Severe disability and even death can result from the inappropriate diagnosis and treatment of a young child's wheezing, which is heterogeneous in its origins and expression. Consequently, a differential diagnosis is necessary to determine the cause and to develop an effective management strategy. Viral-induced wheeze, especially from respiratory syncytial virus (RSV), manifests as a bronchiolitis. Recent reports show that the cysteinyl leukotrienes are an important mediator of the airway effects of RSV infection and that leukotriene receptor antagonists reduce postrespiratory syncytial virus lung symptoms. Exercise-induced bronchoconstriction manifests as wheezing and can be treated or pretreated short-term with inhaled bronchodilators or cromolyn: long-term therapy includes inhaled corticosteroids and leukotriene receptor antagonists. Allergic rhinitis-associated wheeze may be the result of acute exposure to an allergen or simply from nasal dysfunction. Control of allergic rhinitis with intranasal steroids, antihistamines, or leukotriene receptor antagonists could relieve the wheezing. Asthma-associated wheeze requires long-term use of 1 or more daily controller medications. The primary goal is to navigate the child safely through the first episode of wheezing, consider the causes of the wheeze, and then evaluate the need for further therapy. All apparent causes of wheeze should be treated with the idea that if the apparent cause turns out not to be the actual cause, treatment can be safely discontinued.

© 2024 MJH Life Sciences

All rights reserved.